Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Archives of Virology
Published in: Archives of Virology 3/2013

01-03-2013 | Original Article

Protection of guinea pigs by vaccination with a recombinant swinepox virus co-expressing HA1 genes of swine H1N1 and H3N2 influenza viruses

Authors: Jiarong Xu, Deji Yang, Dongyan Huang, Jiaping Xu, Shichao Liu, Huixing Lin, Haodan Zhu, Bao Liu, Chengping Lu

Published in: Archives of Virology | Issue 3/2013

Login to get access

Abstract

Swine influenza (SI) is an acute respiratory infectious disease of swine caused by swine influenza virus (SIV). SIV is not only an important respiratory pathogen in pigs but also a potent threat to human health. Here, we report the construction of a recombinant swinepox virus (rSPV/H3-2A-H1) co-expressing hemagglutinin (HA1) of SIV subtypes H1N1 and H3N2. Immune responses and protection efficacy of the rSPV/H3-2A-H1 were evaluated in guinea pigs. Inoculation of rSPV/H3-2A-H1 yielded neutralizing antibodies against SIV H1N1 and H3N2. The IFN-γ and IL-4 concentrations in the supernatant of lymphocytes stimulated with purified SIV HA1 antigen were significantly higher (P < 0.01) than those of the control groups. Complete protection of guinea pigs against SIV H1N1 or H3N2 challenge was observed. No SIV shedding was detected from guinea pigs vaccinated with rSPV/H3-2A-H1 after challenge. Most importantly, the guinea pigs immunized with rSPV/H3-2A-H1 did not show gross and micrographic lung lesions. However, the control guinea pigs experienced distinct gross and micrographic lung lesions at 7 days post-challenge. Our data suggest that the recombinant swinepox virus encoding HA1 of SIV H1N1 and H3N2 might serve as a promising candidate vaccine for protection against SIV H1N1 and H3N2 infections.
Literature
1.
Caton AJ, Brownlee GG, Yewdell JW, Gerhard W (1982) The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 31:417–427PubMedCrossRef
2.
Donnelly ML, Luke G, Mehrotra A, Li X, Hughes LE, Gani D, Ryan MD (2001) Analysis of the aphthovirus 2A/2B polyprotein ‘cleavage’ mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal ‘skip’. J Gen Virol 82:1013–1025PubMed
3.
Heinen PP, Rijsewijk FA, de Boer-Luijtze EA, Bianchi AT (2002) Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J Gen Virol 83:1851–1859PubMed
4.
Hessel A, Schwendinger M, Holzer GW, Orlinger KK, Coulibaly S, Savidis-Dacho H, Zips ML, Crowe BA, Kreil TR, Ehrlich HJ, Barrett PN, Falkner FG (2011) Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity. PloS one 6:e16247PubMedCrossRef
5.
Hghihghi HR, Read LR, Mohammadi H, Pei Y, Ursprung C, Nagy E, Behboudi S, Haeryfar SM, Sharif S (2011) Characterization of host responses against a recombinant fowlpox virus-vectored vaccine expressing the hemagglutinin antigen of an avian influenza virus. Clin Vaccine Immunol 17:454–463CrossRef
6.
Ito T (2000) Interspecies transmission and receptor recognition of influenza A viruses. Microbiol Immunol 44:423–430PubMed
7.
Larsen DL, Karasin A, Zuckermann F, Olsen CW (2000) Systemic and mucosal immune responses to H1N1 influenza virus infection in pigs. Vet Microbiol 74:117–131PubMedCrossRef
8.
Lin HX, Huang DY, Wang Y, Lu CP, Fan HJ (2011) A novel vaccine against Streptococcus equi ssp. zooepidemicus infections: the recombinant swinepox virus expressing M-like protein. Vaccine 29:7027–7034PubMedCrossRef
9.
Ma W, Vincent AL, Lager KM, Janke BH, Henry SC, Rowland RR, Hesse RA, Richt JA (2010) Identification and characterization of a highly virulent triple reassortant H1N1 swine influenza virus in the United States. Virus genes 40:28–36PubMedCrossRef
10.
Manicassamy B, Medina RA, Hai R, Tsibane T, Stertz S, Nistal-Villan E, Palese P, Basler CF, Garcia-Sastre A (2011) Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines. PLoS Pathog 6:e1000745CrossRef
11.
Masic A, Lu X, Li J, Mutwiri GK, Babiuk LA, Brown EG, Zhou Y (2011) Immunogenicity and protective efficacy of an elastase-dependent live attenuated swine influenza virus vaccine administered intranasally in pigs. Vaccine 28:7098–7108CrossRef
12.
Masic A, Booth JS, Mutwiri GK, Babiuk LA, Zhou Y (2009) Elastase-dependent live attenuated swine influenza A viruses are immunogenic and confer protection against swine influenza A virus infection in pigs. J Virol 83:10198–10210PubMedCrossRef
13.
Moorkamp L, Beineke A, Kaim U, Diesterbeck U, Urstadt S, Czerny CP, Ruberg H, Grosse Beilage E (2008) Swinepox–skin disease with sporadic occurrence. Dtw 115:162–166
14.
Ryman KD, White LJ, Johnston RE, Klimstra WB (2002) Effects of PKR/RNase L-dependent and alternative antiviral pathways on alphavirus replication and pathogenesis. Viral Immunol 15:53–76PubMedCrossRef
15.
Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, Vanin EF, Vignali DA (2004) Correction of multi-gene deficiency in vivo using a single ‘self-cleaving’ 2A peptide-based retroviral vector. Nat Biotechnol 22:589–594PubMedCrossRef
16.
Tian ZJ, Zhou GH, Zheng BL, Qiu HJ, Ni JQ, Yang HL, Yin XN, Hu SP, Tong GZ (2006) A recombinant pseudorabies virus encoding the HA gene from H3N2 subtype swine influenza virus protects mice from virulent challenge. Vet Immunol Immunop 111:211–218CrossRef
17.
Torres V, Barra L, Garcés F, Ordenes K, Leal-Ortiz S, Garner CC, Fernandez F, Zamorano P (2010) A bicistronic lentiviral vector based on the 1D/2A sequence of foot-and-mouth disease virus expresses proteins stoichiometrically. J Biotechnol 146:138–142PubMedCrossRef
18.
Tripathy DN (1999) Swinepox virus as a vaccine vector for swine pathogens. Adv Vet Med 41:463–480PubMedCrossRef
19.
van der Leek ML, Feller JA, Sorensen G, Isaacson W, Adams CL, Borde DJ, Pfeiffer N, Tran T, Moyer RW, Gibbs EP (1994) Evaluation of swinepox virus as a vaccine vector in pigs using an Aujeszky’s disease (pseudorabies) virus gene insert coding for glycoproteins gp50 and gp63. Vet Rec 134:13–18PubMedCrossRef
20.
Van Reeth K, Braeckmans D, Cox E, Van Borm S, van den Berg T, Goddeeris B, De Vleeschauwer A (2009) Prior infection with an H1N1 swine influenza virus partially protects pigs against a low pathogenic H5N1 avian influenza virus. Vaccine 27:6330–6339PubMedCrossRef
21.
Webster RG, Sharp GB, Claas EC (1995) Interspecies transmission of influenza viruses. Am J Resp Crit Care 152:S25–S30
22.
Wesley RD, Tang M, Lager KM (2004) Protection of weaned pigs by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of H3N2 swine influenza virus. Vaccine 22:3427–3434PubMedCrossRef
23.
Xu J, Huang D, Liu S, Lin H, Zhu H, Liu B, Lu C (2012) Immune responses and protection efficacy of a recombinant swinepox virus expressing HA1 against swine H3N2 influenza virus in mice and pigs. Virus Res 167:188–195PubMedCrossRef
24.
Xu J, Huang D, Liu S, Lin H, Zhu H, Liu B, Lu C (2012) Immune responses and protective efficacy of a recombinant swinepox virus expressing HA1 against swine H1N1 influenza virus in mice and pigs. Vaccine 30:3119–3125PubMedCrossRef
Metadata
Title
Protection of guinea pigs by vaccination with a recombinant swinepox virus co-expressing HA1 genes of swine H1N1 and H3N2 influenza viruses
Authors
Jiarong Xu
Deji Yang
Dongyan Huang
Jiaping Xu
Shichao Liu
Huixing Lin
Haodan Zhu
Bao Liu
Chengping Lu
Publication date
01-03-2013
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 3/2013
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-012-1539-9

Other articles of this Issue 3/2013

Archives of Virology 3/2013 Go to the issue

Original Article

Can brucellosis influence the course of chronic hepatitis C in dual infection?

Annotated Sequence Record

Analysis of molecular variation of porcine reproductive and respiratory syndrome virus in Central China from 2006 to 2012

Original Article

Dynamic distribution and tissue tropism of infectious laryngotracheitis virus in experimentally infected chickens

Original Article

First molecular characterization of visna/maedi viruses from naturally infected sheep in Turkey

Brief Report

Isolation of a novel herpesvirus from a Pacific white-sided dolphin

Brief Report

Population structure of blackberry chlorotic ringspot virus in the United States
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits